Summary

Persistence Market Research has recently released a detailed report on the global cutaneous & systemic leishmaniasis market. This report provides an in-depth evaluation of critical market dynamics, including drivers, trends, opportunities, and challenges, offering a thorough understanding of the market structure.

Key Insights:

• Cutaneous & Systemic Leishmaniasis Market Value (2024F): US$ 366.04 million
• Projected Market Value (2031F): USD 448.5 Million
• Global Market Growth Rate (CAGR 2024 to 2031): 2.9%

Cutaneous & Systemic Leishmaniasis Market - Report Scope:

The cutaneous & systemic leishmaniasis market is essential for addressing the treatment and management of leishmaniasis, a parasitic disease prevalent in tropical and subtropical regions. The market caters to various patient groups affected by different forms of the disease, with growth driven by increasing prevalence, growing awareness, and advancements in treatment options.

Market Growth Drivers:

The global cutaneous & systemic leishmaniasis market is driven by several key factors, including the rising prevalence of the disease in tropical regions and the growing awareness about prevention and treatment. The effectiveness of combinational drug therapy has significantly boosted clinical cure rates, leading to better patient outcomes and driving market growth. Additionally, increased investments in research and development by pharmaceutical companies to develop novel treatments are expected to create new opportunities in the market. Favorable reimbursement policies by governments and private insurers further support market expansion by making treatment more accessible to patients.

Market Restraints:

Despite its growth potential, the cutaneous & systemic leishmaniasis market faces several challenges. The high cost of treatment, driven by the expensive drugs used to combat the disease, presents a significant barrier to market growth. Additionally, the risk of serious adverse effects from these treatments can deter both patients and healthcare providers from pursuing certain therapies. While ongoing research aims to reduce these side effects, the current limitations of treatment options pose a restraint on the market.

Market Opportunities:

The cutaneous & systemic leishmaniasis market presents substantial growth opportunities, particularly through the development of new and improved treatment options. Ongoing research and clinical trials are expected to yield innovative therapies with higher efficacy and fewer side effects. These advancements, coupled with increasing investments in healthcare infrastructure and supportive government policies, are likely to drive the market forward. Moreover, the growing awareness and education efforts regarding leishmaniasis are expected to boost the adoption of available treatments, thereby expanding the market.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the cutaneous & systemic leishmaniasis market globally?
• Which treatment options are leading the demand in various patient demographics?
• How are technological advancements influencing the competitive landscape of the cutaneous & systemic leishmaniasis market?
• Who are the key players in the cutaneous & systemic leishmaniasis market, and what strategies are they employing to enhance their market presence?
• What are the emerging trends and future prospects in the global cutaneous & systemic leishmaniasis market?

Competitive Intelligence and Business Strategy:

Leading players in the global cutaneous & systemic leishmaniasis market, including companies such as GlaxoSmithKline, Sanofi, and Novartis, focus on innovation, drug development, and strategic partnerships to gain a competitive edge. These companies invest in research and development to enhance treatment efficacy, reduce side effects, and expand the range of therapeutic options available. Collaborations with research institutions and healthcare organizations facilitate the advancement of clinical trials and the introduction of new therapies. Emphasis on patient-centric solutions and access to affordable treatment drives growth and strengthens market positioning in the dynamic cutaneous & systemic leishmaniasis industry.

Key Companies Profiled:

• GlaxoSmithKline plc.
• Gilead Sciences, Inc.
• Profounda Pharmaceuticals
• Knight Therapeutics Inc.
• Janssen Global Services, LLC
• Albert David Ltd
• Jubilant Life Sciences Ltd.
• Novartis AG
• Sanofi
• Endo Pharmaceuticals Inc
• Bristol-Myers Squibb Company
• United Biotech Pvt. Ltd.

Cutaneous & Systemic Leishmaniasis Market Categorization

Cutaneous & Systemic Leishmaniasis Market by By Drug Class

• Pentavalent Antimonials
• Antifungal Drugs
• Anti-Lesihmanial/Antimicrobial Drugs

Cutaneous & Systemic Leishmaniasis Market By Route of Administration

• Oral
• Injectable
• Topical

Cutaneous & Systemic Leishmaniasis Market By Indication

• Cutaneous Leishmaniasis
• Mucosal Leishmaniasis
• Visceral Leishmaniasis

Cutaneous & Systemic Leishmaniasis Market By Distribution Channel

• Hospital Pharmacies,
• Retail Pharmacies
• Drug Stores
• Online Pharmacies

Cutaneous & Systemic Leishmaniasis Market by Region

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East & Africa (MEA)

ページTOPに戻る

Table of Contents

1. Executive Summary
1.1. Global Market Outlook
1.2. Market Analysis
1.3. PMR Analysis and Recommendations
1.4. Wheel of Fortune
2. Market Overview
2.1. Market Definition
2.2. Market Taxonomy
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation Trends
3.3. New Launches / Patents/Market Background
4. Key Success Factors
4.1. Product Adoption / Awareness Analysis
4.2. Pipeline Assessment
4.3. Leishmaniasis Epidemiology
5. Global Market Demand / Consumption (value or size in US$ Mn) Analysis
5.1. Historical Market Value (US$ Mn) Analysis
5.2. Current and Future Market Value (US$ Mn) Projections
5.2.1. Y-o-Y Growth Trend Analysis
5.2.2. Absolute $ Opportunity Analysis
6. Market Context
6.1. Key Regulations
6.2. Macro-Economic Factors
6.3. Forecast Factors – Relevance & Impact
6.4. Market Dynamics
6.4.1. Drivers
6.4.2. Restraints
6.4.3. Opportunity Analysis
7. Global Cutaneous and Systemic Leishmaniasis Analysis 2019-2023 and Forecast 2024-2031, By Drug Class
7.1. Introduction
7.1.1. Market Value Share Analysis By Drug Class
7.1.2. Y-o-Y Growth Analysis By Drug Class
7.2. Historical Market Size and Volume Analysis By Drug Class 2019-2023
7.3. Market Size and Volume Forecast By Drug Class 2024-2031
7.3.1. Pentavalent Antimonials
7.3.2. Antifungal Drugs
7.3.3. Antimicrobial / Anti-leishmanial
7.4. Market Attractiveness Analysis By Drug Class
8. Global Cutaneous and Systemic Leishmaniasis Analysis 2019-2023 and Forecast 2024-2031, By Route of Administration
8.1. Introduction
8.1.1. Market Value Share Analysis By Route of Administration
8.1.2. Y-o-Y Growth Analysis By Route of Administration
8.2. Historical Market Size and Volume Analysis By Route of Administration 2019-2023
8.3. Market Size and Volume Forecast By Route of Administration 2024-2031
8.3.1. Oral
8.3.2. Injectable
8.3.3. Topical
8.4. Market Attractiveness Analysis By Drug Class
9. Global Cutaneous and Systemic Leishmaniasis Analysis 2019-2023 and Forecast 2024-2031, By Indication Type
9.1. Introduction
9.1.1. Market Value Share Analysis By Indication Type
9.1.2. Y-o-Y Growth Analysis By Indication Type
9.2. Historical Market Size and Volume Analysis By Indication Type 2019-2023
9.3. Market Size and Volume Forecast By Indication Type 2024-2031
9.3.1. Cutaneous Leishmaniasis
9.3.2. Mucosal Leishmaniasis
9.3.3. Visceral Leishmaniasis
9.4. Market Attractiveness Analysis By Indication Type
10. Global Cutaneous and Systemic Leishmaniasis Market Analysis 2019-2023 and Forecast 2024-2031, By Distribution Channel
10.1. Introduction
10.1.1. Market Value Share Analysis By Distribution Channel
10.1.2. Y-o-Y Growth Analysis By Distribution Channel
10.2. Historical Market Size and Volume Analysis By Distribution Channel, 2019-2023
10.3. Market Size and Volume Forecast By Distribution Channel 2024-2031
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Drug Stores
10.3.4. Online Pharmacies
10.4. Market Attractiveness Analysis By Distribution Channel
11. Global Cutaneous and Systemic Leishmaniasis Market Analysis 2019-2023 and Forecast 2024-2031, By Region
11.1. Introduction
11.1.1. Market Value Share Analysis By Region
11.1.2. Y-o-Y Growth Analysis By Region
11.2. Historical Market Size and Volume Analysis By Region 2019-2023
11.3. Market Size and Volume Forecast By Region 2024-2031
11.3.1. North America
11.3.2. Latin America
11.3.3. Europe
11.3.4. Asia Pacific Excl. Japan
11.3.5. Japan
11.3.6. Oceania
11.3.7. Middle East and Africa Market Attractiveness Analysis By Region
12. North America Cutaneous and Systemic Leishmaniasis Market Analysis 2019-2023 and Forecast 2024-2031
12.1. Introduction
12.2. Historical Market Size and Volume Analysis By Market Segments, 2019-2023
12.3. Market Size and Volume Forecast By Market Segments, 2024-2031
12.3.1. By Country
12.3.1.1. U.S.
12.3.1.2. Canada
12.3.2. By Drug Class
12.3.3. By Route of Administration
12.3.4. By Indication Type
12.3.5. By Distribution Channel
12.4. Market Attractiveness Analysis
12.5. Key Market Participants – Intensity Mapping
12.6. Drivers and Restraints – Impact Analysis
13. Latin America Cutaneous and Systemic Leishmaniasis Market Analysis 2019-2023 and Forecast 2024-2031
13.1. Asia Pacific Excl. Japan
13.2. Japan
13.3. Oceania
13.4. Middle East and Africa Market Attractiveness Analysis By Region
14. North America Cutaneous and Systemic Leishmaniasis Market Analysis 2019-2023 and Forecast 2024-2031
14.1. Introduction
14.2. Historical Market Size and Volume Analysis By Market Segments, 2019-2023
14.3. Market Size and Volume Forecast By Market Segments, 2024-2031
14.3.1. By Country
14.3.1.1. U.S.
14.3.1.2. Canada
14.3.2. By Drug Class
14.3.3. By Route of Administration
14.3.4. By Indication Type
14.3.5. By Distribution Channel
14.4. Market Attractiveness Analysis
14.5. Key Market Participants – Intensity Mapping
14.6. Drivers and Restraints – Impact Analysis
15. Latin America Cutaneous and Systemic Leishmaniasis Market Analysis 2019-2023 and Forecast 2024-2031
15.1. Introduction
15.2. Historical Market Size and Volume Analysis By Market Segments, 2019-2023 Market Size
15.3. Market Size and Volume Forecast By Market Segments, 2024-2031
15.3.1. By Country
15.3.1.1. Brazil
15.3.1.2. Mexico
15.3.1.3. Rest of Latin America
15.3.2. By Drug Class
15.3.3. By Route of Administration
15.3.4. By Indication Type
15.3.5. By Distribution Channel
15.4. Market Attractiveness Analysis
15.5. Key Market Participants – Intensity Mapping
15.6. Drivers and Restraints – Impact Analysis
16. Europe America Cutaneous and Systemic Leishmaniasis Market Analysis 2019-2023 and Forecast 2024-2031
16.1. Introduction
16.2. Historical Market Size (US$ Mn) Trend Analysis By Country, 2019-2023
16.3. Market Size and Volume Forecast By Market Segments, 2024-2031
16.3.1. By Country
16.3.1.1. Germany
16.3.1.2. Italy
16.3.1.3. France
16.3.1.4. U.K.
16.3.1.5. Spain
16.3.1.6. BENELUX
16.3.1.7. Nordic
16.3.1.8. Russia
16.3.1.9. Rest of Europe
16.3.2. By Drug Class
16.3.3. By Route of Administration
16.3.4. By Indication Type
16.3.5. By Distribution Channel
16.4. Market Attractiveness Analysis
16.5. Key Market Participants – Intensity Mapping
16.6. Drivers and Restraints – Impact Analysis
17. Asia-Pacific Excluding Japan (APEJ) Cutaneous and Systemic Leishmaniasis Market Analysis 2019-2023 and Forecast 2024-2031
17.1. Introduction
17.2. Historical Market Size (US$ Mn) Trend Analysis By Country, 2019-2023
17.3. Market Size and Volume Forecast By Market Segments, 2024-2031
17.3.1. By Country
17.3.1.1. China
17.3.1.2. India
17.3.1.3. South Korea
17.3.1.4. ASEAN
17.3.1.5. Rest of APEJ
17.3.2. By Drug Class
17.3.3. By Route of Administration
17.3.4. By Indication Type
17.3.5. By Distribution Channel
17.4. Market Attractiveness Analysis
17.5. Key Market Participants - Intensity Mapping
17.6. Drivers and Restraints - Impact Analysis
18. Japan Cutaneous and Systemic Leishmaniasis Market Analysis 2019-2023 and Forecast 2024-2031
18.1. Introduction
18.2. Historical Market Size and Volume Analysis By Market Segments,
18.3. 2019-2023
18.4. Market Size and Volume Forecast By Market Segments, 2024-2031
18.4.1. By Drug Class
18.4.2. By Route of Administration
18.4.3. By Indication Type
18.4.4. By Distribution Channel
18.5. Market Attractiveness Analysis
18.6. Key Market Participants – Intensity Mapping
18.7. Drivers and Restraints – Impact Analysis
19. Oceania Cutaneous and Systemic Leishmaniasis Market Analysis 2019-2023 and Forecast 2024-2031
19.1. Introduction
19.2. Historical Market Size (US$ Mn) Trend Analysis By Country, 2019-2023
19.3. Market Size and Volume Forecast By Market Segments, 2024-2031
19.3.1. By Country
19.3.1.1. Australia
19.3.1.2. New Zealand
19.3.2. By Drug Class
19.3.3. By Route of Administration
19.3.4. By Indication Type
19.3.5. By Distribution Channel
19.4. Market Attractiveness Analysis
19.5. Key Market Participants - Intensity Mapping
19.6. Drivers and Restraints - Impact Analysis
20. Middle East and Africa (MEA) Cutaneous and Systemic Leishmaniasis Market Analysis 2019-2023 and Forecast 2024-2031
20.1. Introduction
20.2. Historical Market Size (US$ Mn) Trend Analysis By Country, 2019-2023
20.3. Market Size and Volume Forecast By Market Segments, 2024-2031
20.3.1. By Country
20.3.1.1. Northern Africa
20.3.1.2. GCC Countries
20.3.1.3. Turkey
20.3.1.4. South Africa
20.3.1.5. Rest of MEA
20.3.2. By Drug Class
20.3.3. By Route of Administration
20.3.4. By Indication Type
20.3.5. By Distribution Channel
21. Market Attractiveness Analysis
21.1. Tier Structure Analysis
21.2. Market Presence Analysis
21.2.1. By Region
21.2.2. Product Portfolio
22. Competition Analysis
22.1. Competition Dashboard
22.2. Company Deep Dive
22.2.1. GlaxoSmithKline plc.
22.2.1.1. Overview
22.2.1.2. Product and Application Portfolio
22.2.1.3. Production Footprint
22.2.1.4. Sales Footprint
22.2.1.5. Analyst Commentary
22.2.2. Gilead Sciences, Inc.
22.2.2.1. Overview
22.2.2.2. Product and Application Portfolio
22.2.2.3. Production Footprint
22.2.2.4. Sales Footprint
22.2.2.5. Analyst Commentary
22.2.3. Profounda Pharmaceuticals
22.2.3.1. Overview
22.2.3.2. Product and Application Portfolio
22.2.3.3. Production Footprint
22.2.3.4. Sales Footprint
22.2.3.5. Analyst Commentary
22.2.4. Knight Therapeutics Inc.
22.2.4.1. Overview
22.2.4.2. Product and Application Portfolio
22.2.4.3. Production Footprint
22.2.4.4. Sales Footprint
22.2.4.5. Analyst Commentary
22.2.5. Janssen Global Services, LLC
22.2.5.1. Overview
22.2.5.2. Product and Application Portfolio
22.2.5.3. Production Footprint
22.2.5.4. Sales Footprint
22.2.5.5. Analyst Commentary
22.2.6. Albert David Ltd
22.2.6.1. Overview
22.2.6.2. Product and Application Portfolio
22.2.6.3. Production Footprint
22.2.6.4. Sales Footprint
22.2.6.5. Analyst Commentary
22.2.7. Jubilant Life Sciences Ltd.
22.2.7.1. Overview
22.2.7.2. Product and Application Portfolio
22.2.7.3. Production Footprint
22.2.7.4. Sales Footprint
22.2.7.5. Analyst Commentary
22.2.8. Novartis AG
22.2.8.1. Overview
22.2.8.2. Product and Application Portfolio
22.2.8.3. Production Footprint
22.2.8.4. Sales Footprint
22.2.8.5. Analyst Commentary
22.2.9. Sanofi
22.2.9.1. Overview
22.2.9.2. Product and Application Portfolio
22.2.9.3. Production Footprint
22.2.9.4. Sales Footprint
22.2.9.5. Analyst Commentary
22.2.10. Endo Pharmaceuticals Inc
22.2.10.1. Overview
22.2.10.2. Product and Application Portfolio
22.2.10.3. Production Footprint
22.2.10.4. Sales Footprint
22.2.10.5. Analyst Commentary
22.2.11. Bristol-Myers Squibb Company
22.2.11.1. Overview
22.2.11.2. Product and Application Portfolio
22.2.11.3. Production Footprint
22.2.11.4. Sales Footprint
22.2.11.5. Analyst Commentary
22.2.12. United Biotech Pvt. Ltd.
22.2.12.1. Overview
22.2.12.2. Product and Application Portfolio
22.2.12.3. Production Footprint
22.2.12.4. Sales Footprint
22.2.12.5. Analyst Commentary
23. Research Methodology